Three-Month Symptom Profiles Among Symptomatic Adults With Positive and Negative Severe Acute Respiratory Syndrome Coronavirus 2 Tests: A Prospective Cohort Study From the INSPIRE Group
| العنوان: | Three-Month Symptom Profiles Among Symptomatic Adults With Positive and Negative Severe Acute Respiratory Syndrome Coronavirus 2 Tests: A Prospective Cohort Study From the INSPIRE Group |
|---|---|
| المؤلفون: | Erica S Spatz, Michael Gottlieb, Lauren E Wisk, Jill Anderson, Anna Marie Chang, Nicole L Gentile, Mandy J Hill, Ryan M Huebinger, Ahamed H Idris, Jeremiah Kinsman, Katherine Koo, Shu-Xia Li, Samuel McDonald, Ian D Plumb, Robert M Rodriguez, Sharon Saydah, Benjamin Slovis, Kari A Stephens, Elizabeth R Unger, Ralph C Wang, Huihui Yu, Bala Hota, Joann G Elmore, Robert A Weinstein, Arjun Venkatesh |
| المصدر: | Clinical Infectious Diseases. 76:1559-1566 |
| بيانات النشر: | Oxford University Press (OUP), 2022. |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | Microbiology (medical), Infectious Diseases |
| الوصف: | Background Long-term symptoms following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are a major concern, yet their prevalence is poorly understood. Methods We conducted a prospective cohort study comparing adults with SARS-CoV-2 infection (coronavirus disease-positive [COVID+]) with adults who tested negative (COVID−), enrolled within 28 days of a Food and Drug Administration (FDA)-approved SARS-CoV-2 test result for active symptoms. Sociodemographic characteristics, symptoms of SARS-CoV-2 infection (assessed with the Centers for Disease Control and Prevention [CDC] Person Under Investigation Symptom List), and symptoms of post-infectious syndromes (ie, fatigue, sleep quality, muscle/joint pains, unrefreshing sleep, and dizziness/fainting, assessed with CDC Short Symptom Screener for myalgic encephalomyelitis/chronic fatigue syndrome) were assessed at baseline and 3 months via electronic surveys sent via text or email. Results Among the first 1000 participants, 722 were COVID+ and 278 were COVID−. Mean age was 41.5 (SD 15.2); 66.3% were female, 13.4% were Black, and 15.3% were Hispanic. At baseline, SARS-CoV-2 symptoms were more common in the COVID+ group than the COVID− group. At 3 months, SARS-CoV-2 symptoms declined in both groups, although were more prevalent in the COVID+ group: upper respiratory symptoms/head/eyes/ears/nose/throat (HEENT; 37.3% vs 20.9%), constitutional (28.8% vs 19.4%), musculoskeletal (19.5% vs 14.7%), pulmonary (17.6% vs 12.2%), cardiovascular (10.0% vs 7.2%), and gastrointestinal (8.7% vs 8.3%); only 50.2% and 73.3% reported no symptoms at all. Symptoms of post-infectious syndromes were similarly prevalent among the COVID+ and COVID− groups at 3 months. Conclusions Approximately half of COVID+ participants, as compared with one-quarter of COVID− participants, had at least 1 SARS-CoV-2 symptom at 3 months, highlighting the need for future work to distinguish long COVID. Clinical Trials Registration NCT04610515. |
| تدمد: | 1537-6591 1058-4838 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_________::f1f5c12fca72f48e6b7d0970bf6c18ea https://doi.org/10.1093/cid/ciac966 |
| حقوق: | CLOSED |
| رقم الأكسشن: | edsair.doi...........f1f5c12fca72f48e6b7d0970bf6c18ea |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15376591 10584838 |
|---|